Signe Schmidt

Summary

Affiliation: Copenhagen University Hospital
Country: Denmark

Publications

  1. pmc Model-based closed-loop glucose control in type 1 diabetes: the DiaCon experience
    Signe Schmidt
    Department of Endocrinology, Copenhagen University Hospital Hvidovre, Kettegard Alle 30, 2650 Hvidovre, Denmark
    J Diabetes Sci Technol 7:1255-64. 2013
  2. doi Sensor-augmented pump therapy at 36 months
    Signe Schmidt
    Department of Endocrinology, Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark
    Diabetes Technol Ther 14:1174-7. 2012
  3. doi Effects of everyday life events on glucose, insulin, and glucagon dynamics in continuous subcutaneous insulin infusion-treated type 1 diabetes: collection of clinical data for glucose modeling
    Signe Schmidt
    Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark
    Diabetes Technol Ther 14:210-7. 2012
  4. ncbi Continuous glucose monitoring-enabled insulin-pump therapy in diabetic pregnancy
    Anna L Secher
    Center for Pregnant Women with Diabetes, Department of Endocrinology, Rigshospitalet, Copenhagen, Denmark
    Acta Obstet Gynecol Scand 89:1233-7. 2010
  5. pmc Use of an automated bolus calculator in MDI-treated type 1 diabetes: the BolusCal Study, a randomized controlled pilot study
    Signe Schmidt
    Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark
    Diabetes Care 35:984-90. 2012
  6. doi Glucose sensor excludes hypoglycaemia as cause of death
    Signe Schmidt
    Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark
    Diabetes Res Clin Pract 96:e30-2. 2012

Detail Information

Publications6

  1. pmc Model-based closed-loop glucose control in type 1 diabetes: the DiaCon experience
    Signe Schmidt
    Department of Endocrinology, Copenhagen University Hospital Hvidovre, Kettegard Alle 30, 2650 Hvidovre, Denmark
    J Diabetes Sci Technol 7:1255-64. 2013
    ..The stochastic part is identical for all patients but identified from data from a single patient. Results of the first clinical feasibility test of the algorithm are presented...
  2. doi Sensor-augmented pump therapy at 36 months
    Signe Schmidt
    Department of Endocrinology, Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark
    Diabetes Technol Ther 14:1174-7. 2012
    ..This follow-up study investigates the metabolic and psychosocial effects of sensor-augmented pump (SAP) therapy in adults with type 1 diabetes 36 months after therapy start...
  3. doi Effects of everyday life events on glucose, insulin, and glucagon dynamics in continuous subcutaneous insulin infusion-treated type 1 diabetes: collection of clinical data for glucose modeling
    Signe Schmidt
    Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark
    Diabetes Technol Ther 14:210-7. 2012
    ..To obtain type 1 diabetes (T1D) data for the modeling of glucose metabolism, we designed and conducted a clinical study...
  4. ncbi Continuous glucose monitoring-enabled insulin-pump therapy in diabetic pregnancy
    Anna L Secher
    Center for Pregnant Women with Diabetes, Department of Endocrinology, Rigshospitalet, Copenhagen, Denmark
    Acta Obstet Gynecol Scand 89:1233-7. 2010
    ..4% in early pregnancy. The patient was satisfied with this therapy, pre-eclampsia did not occur, and the child was born at term without neonatal morbidity. CGM-enabled insulin-pump therapy appears feasible in diabetic pregnancies...
  5. pmc Use of an automated bolus calculator in MDI-treated type 1 diabetes: the BolusCal Study, a randomized controlled pilot study
    Signe Schmidt
    Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark
    Diabetes Care 35:984-90. 2012
    ..Furthermore, to test the feasibility of teaching FIIT in a 3-h structured course...
  6. doi Glucose sensor excludes hypoglycaemia as cause of death
    Signe Schmidt
    Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark
    Diabetes Res Clin Pract 96:e30-2. 2012
    ..This report describes an unexpected death in a 44-year-old man with Type 1 diabetes treated with sensor-augmented pump therapy. Continuous glucose monitoring data proved useful in determining the cause of death...